Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Free Report) - Analysts at Alliance Global Partners boosted their FY2024 earnings per share estimates for shares of Curaleaf in a research report issued to clients and investors on Thursday, November 7th. Alliance Global Partners analyst A. Grey now forecasts that the company will post earnings per share of ($0.26) for the year, up from their previous estimate of ($0.27). The consensus estimate for Curaleaf's current full-year earnings is ($0.25) per share. Alliance Global Partners also issued estimates for Curaleaf's Q4 2024 earnings at ($0.08) EPS, Q1 2025 earnings at ($0.07) EPS, Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.25) EPS.
CURLF has been the topic of a number of other reports. Cormark lowered shares of Curaleaf from a "moderate buy" rating to a "hold" rating in a report on Thursday. Needham & Company LLC restated a "buy" rating and set a $6.25 target price on shares of Curaleaf in a report on Thursday, August 8th.
Read Our Latest Research Report on CURLF
Curaleaf Stock Down 22.1 %
Shares of CURLF traded down $0.47 on Monday, hitting $1.66. The company's stock had a trading volume of 3,126,765 shares, compared to its average volume of 702,513. The company has a quick ratio of 0.50, a current ratio of 1.09 and a debt-to-equity ratio of 0.83. The firm has a market capitalization of $1.08 billion, a price-to-earnings ratio of -5.72 and a beta of 0.86. The firm's fifty day moving average price is $2.95 and its 200-day moving average price is $3.77. Curaleaf has a fifty-two week low of $1.64 and a fifty-two week high of $6.40.
Curaleaf Company Profile
(
Get Free Report)
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Read More
Before you consider Curaleaf, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.
While Curaleaf currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.